Approved for the treatment of refractory patients with locally advanced basal cell carcinoma.
Patients who have undergone unsuccessful surgery or radiation treatment, although were not eligible for either, can initiate treatment.
A hedgehog inhibitor.
Phase 2 BOLT study and overall response rate of 58%.
The most serious risks are: Rhabdomyolysis and embryofetal toxicity.